Prebona receives positive results from the In-Vivo study

Simrishamn – Prebona AB (publ) today announces that the company has received positive results from an In Vivo study with the company’s substance AgSol.

The purpose of the study was to make an in vivo assessment of the antibacterial effect of Prebona’s substance, AgSol. The study was a treatment study in which bacteria are infected intraperitoneally, that is, in the abdominal cavity, with the bacterium Staphylococcus aureus and then treated with AgSol to determine a possible reduction of bacteria. The results of the study showed a significant reduction in bacteria in the examined organs. The study was conducted in collaboration with Uppsala University and the Department of Medical Biochemistry and Microbiology (IMBIM).

Prebona, together with IMBIM, has previously conducted a number of studies of AgSol to demonstrate AgSol’s ability to enhance the effect of existing antibiotics. Its potentiating effects have been studied together with a number of clinically relevant antibiotics. The in vitro studies that have been performed previously show that the substance clearly enhances the effect of various types of existing antibiotics. Studies have also been carried out with resistant bacteria and a positive effect has also been demonstrated there.

– It is very gratifying that we also get such good results regarding the antibacterial effect of AgSol on our own in In-Vivo models, says Patrik Bernstein, CEO Prebona AB. Now, in the next step, we will repeat the study to further determine the result and expand the study slightly, concludes Patrik Bernstein.

For further information contact:

Patrik Bernstein, CEO, Phone +46 70 638 2678, E-mail: patrik.bernstein@prebona.com